A strengthening financial division and a growing sales backlog portend a brightening future for GE, but the consolidated numbers coming from GE for 3Q were well below par.
GE’s 3Q numbers fall
A strengthening financial division and a growing sales backlog portend a brightening future for GE, but the consolidated numbers coming from GE for 3Q were well below par. In a financial release Oct. 16, the company reported that revenues fell to $37.8 billion, off 20% compared to the previous year’s third quarter, and earnings fell to $2.5 billion, down 51% from the previous year period. A breakdown of data regarding financial performance related to healthcare products and services were not immediately available.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.